Does Lacosamide Affect Blood Pressure?
Lacosamide, an anticonvulsant used for partial-onset seizures, lists hypertension as a reported adverse reaction in clinical data. In placebo-controlled trials, hypertension occurred in 2% of lacosamide-treated patients versus 1% on placebo, indicating a potential link but low incidence.[1][2]
Evidence from Clinical Trials and Post-Marketing Reports
Pooled data from three multicenter, double-blind, placebo-controlled trials (N=1,298 adults) showed hypertension in 1-3% of patients on lacosamide doses of 200-600 mg/day, typically emerging within weeks of starting treatment. Post-marketing surveillance has noted cases of blood pressure increases, sometimes severe, though causality is not always confirmed. No direct mechanism explains worsening hypertension, but the drug's sodium channel modulation may influence vascular tone indirectly.[1][3]
Who Might Be at Risk?
Patients with pre-existing hypertension or cardiovascular conditions report higher rates. Elderly patients and those on 400-600 mg/day doses show elevated risk (up to 3%). Concomitant use with antihypertensives or drugs affecting sodium levels (e.g., diuretics) could amplify effects, though no specific interactions are proven to worsen hypertension.[1][2]
What Do Doctors Monitor and Recommend?
Guidelines advise baseline blood pressure checks before starting lacosamide, with regular monitoring during titration. Dose adjustments or discontinuation resolve symptoms in most cases. The FDA label flags hypertension as an adverse event but not a contraindication.[1]
How Common Is This Compared to Other Antiepileptics?
| Drug | Hypertension Incidence in Trials |
|------|---------------------------------|
| Lacosamide | 1-3% [1] |
| Levetiracetam | <1% [4] |
| Carbamazepine | 1-2% [4] |
| Lamotrigine | Rare (<1%) [4] |
Lacosamide's rate is slightly higher than some alternatives but remains uncommon overall.
[1]: Vimpat (lacosamide) Prescribing Information, UCB, Inc.
[2]: Clinical Pharmacology Review, FDA Approval NDA 22-253
[3]: VigiBase WHO Pharmacovigilance Database Summary
[4]: Epilepsia Journal Meta-Analysis on AED Adverse Events (2019)